GoodRx (GDRX) reported earnings on Mon 9 May 22 (a/h)

 ** charts before earnings **

** charts after earnings **

 

GoodRx beats by $0.02, beats on revs; guides Q2 revs below consensus; unlikely to achieve prior FY22 guidance 

• Reports Q1 (Mar) earnings of $0.10 per share, excluding non-recurring items, $0.02 better than the S&P Capital IQ Consensus of $0.08; revenues rose 26.7% year/year to $203.3 mln vs the $200.61 mln S&P Capital IQ Consensus.
  • 6.4 mln monthly active users, +12% yr/yr. 
• Co issues downside guidance for Q2, sees Q2 revs of ~$190 mln vs. $216.02 mln S&P Capital IQ Consensus.
• At this time, we believe it is unlikely we will be able to achieve the FY 2022 guidance we provided on our fourth quarter earnings call. We will not be providing full year expectations at this time as the full year impact of the grocer issue is difficult to estimate because there are several variables including, among others, eventual consumer pricing and returning usage levels that have yet to be determined.